Myriad myRisk Hereditary Cancer Panel

Hereditary Cancer Risk Assessment and Testing is essential to optimize patients' medical management.

  • A 25-gene panel for the identification of clinically significant mutations impacting inherited risks for eight important cancers: breast, colorectal, ovarian,endometrial, gastric, pancreatic, melanoma and prostate.
  • Blends genetic test status AND personal/family cancer history into clinically  significant risk assessment and follow-up.
  • Provides specific management recommendations for patients testing positive AND negative based on guidelines of leading professional medical societies.


Myriad myRisk advances Hereditary Cancer Testing with comprehensive knowledge of cancer risk and management

>99.92% Validated Analytical Sensitivity

Technical method is using NGS, Sanger sequencing and large rearrangement analysis.